Celcuity, Inc. $CELC Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in Celcuity, Inc. (NASDAQ:CELC) by 111.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 906,595 shares of the company’s stock after purchasing an additional 477,643 shares during the quarter. Wellington Management Group LLP’s holdings in Celcuity were worth $94,848,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. PNC Financial Services Group Inc. raised its position in shares of Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after purchasing an additional 86 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Celcuity by 15.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock worth $99,000 after buying an additional 124 shares during the last quarter. US Bancorp DE increased its stake in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares in the last quarter. Intech Investment Management LLC increased its stake in Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after buying an additional 183 shares in the last quarter. Finally, Aristides Capital LLC raised its holdings in shares of Celcuity by 2.0% during the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock valued at $1,526,000 after acquiring an additional 303 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

Shares of Celcuity stock opened at $91.98 on Wednesday. Celcuity, Inc. has a one year low of $44.42 and a one year high of $151.02. The company has a market cap of $4.50 billion, a price-to-earnings ratio of -21.39 and a beta of 0.21. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. The business’s 50 day moving average price is $94.66 and its 200 day moving average price is $106.96.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, research analysts predict that Celcuity, Inc. will post -4.75 EPS for the current year.

Analyst Ratings Changes

CELC has been the topic of several research reports. Guggenheim raised their target price on Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Craig Hallum reiterated a “buy” rating and set a $178.00 price target on shares of Celcuity in a research report on Wednesday, July 15th. Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research note on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $154.55.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.